Articles On Telix Pharmaceuticals (ASX:TLX)

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is having a strong session. At the time of writing, the ASX 200 healthcare stock is up almost 12% to $10.94. This follows the release of the company’s half-year results. Telix share pr...

Telix (ASX:TLX) has reported total revenue of $220.8 million for the six months to the end of June 2023, driven by growth in prostate cancer imagined agent Illuccix.

MELBOURNE, Australia, Aug. 23, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise stated.[...

Buying any S&P/ASX 200 Index (ASX: XJO) stock undoubtedly comes with risks. But if you pick the right one and hold it for a long time, extraordinary riches can come about. Even though the Australian bourse is famous for its dividend st...

MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuc...

Telix Pharmaceuticals (TLX) doses its first Chinese patient in the phase III study of TLX591-CDx (Illuccix) with Grand Pharmaceutical Group Illuccix is employed for positron emission tomography (PET) imaging of prostate cancer The Chi...

MELBOURNE, Australia, Aug. 8, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[1...

How do you spot multibagger stocks? Which sectors can you find them in, and which ASX stocks have good potential? Stockhead reached out to VP Capital’s co-founder, John So   As the name suggests, multibaggers are stocks that can generate...

China’s export controls on gallium and germanium come into effect today with licensing procedures with provincial governments now required to export them freely. Both metals are critical components in semiconductor chips, the building block...

Oncology radiology leader Telix Pharmaceuticals is taking on the US, Tim Boreham reports. By Tim Boreham ASX Code: ((TLX)) Share price: $11.26 Shares on issue: 318,808,268 Market cap: $3.58 billion Chief executive officer: Dr Christian Behr...

Australian Eagle Asset Management is the top performing fund manager over a five-year period with their Equity Strategy Fund delivering an impressive return of 11.6 per cent per annum, compared to the ASX 100 Accumulation Index which return...

In this week's Weekly Insights:-Opportunities With A Five Year Horizon-Company Reports: Early Trends-Company Reports: Inflation-Company Reports: Conviction-Company Reports: Technology Sector-REITs In FocusBy Rudi Filapek-Vandyck, Editor FNA...

The S&P/ASX 200 Index (ASX: XJO) has suffered a disappointing start to the trading week this Monday. After initially rising with enthusiasm, the ASX 200 spent most of the trading session running out of steam. By market close, the...

The ASX 200 closed -0.10% in the red today, after feeling flat all day Sectors wise, Energy stocks carried the torch with enthusiasm, while Materials wasn’t let anywhere near said torch Notable performers today: pharma stock Telix (ASX:TLX...

Shares closed flattish as Aussie jobless rate falls to 3.5% Earnings season heats up as a handful of miners give updates China keeps cash rate unchanged, dashing market hopes   Local shares closed flat on Thursday as traders assessed the...

The S&P/ASX 200 Index (ASX: XJO) is on form again and on track to record a small gain. In afternoon trade, the benchmark index is up 0.2% to 7,340 points. Four ASX shares that have failed to follow the market higher today are listed...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has come under pressure on Thursday. In morning trade, the radiopharmaceutical company’s shares are down 17% to $10.06. Why is the Telix share price crashing? Investors have been selli...

World Overnight SPI Overnight 7286.00 + 2.00 0.03% S&P ASX 200 7323.70 + 39.90 0.55% S&P500 4565.72 + 10.74 0.24% Nasdaq Comp 14358.02 + 4.38 0.03% DJIA 35061.21 + 109.28 0.31% S&P500 VIX 13.76 + 0.46 3.46% US 10...

MELBOURNE, Australia, July 19, 2023 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023...

MELBOURNE, Australia, July 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation...

Highlights Telix Pharmaceuticals is a radiopharmaceutical company focusing on the development of diagnostic and therapeutic radiopharmaceutical products For its Q1FY23, ended 31 March 2023, the company reported a revenue of AUD 100.1mn...

Fancy getting money without having to work for it? So do I. Believe it or not, it is possible for the average person on the street to create a handy source of passive income. In this article, I’ll explore how you can invest in ASX shares...

Telix Pharmaceuticals Limited (ASX:TLX) is a Melbourne-headquartered $3.9 billion company which recently entered the Montgomery and Australian Eagle portfolios and seems to have very exciting prospects. To backtrack, Telix’s targeted radiat...

What will the second half have in store for investors? How investors can play geopolitics and recession themes Stockhead reached out to Bell Direct’s Brady Wulff, who gave her predictions    There’s been a lot of drama in the first half o...

From box televisions to the World Wide Web, and brick phones to smartphones, artificial intelligence (AI) has been transforming the way humans process information for decades. According to Next Move Strategy Consulting, the AI market is...

In this week’s video insight David Buckland discusses two Australian biomedical companies, Pro-Medicus (ASX:PME) and Telix Pharmaceuticals (ASX:TLX) which are gaining global recognition. Pro-Medicus specialises in imaging software and has e...

The last financial year was a good one for the S&P/ASX 200 Index (ASX: XJO). The benchmark index carved out a sizeable return of 9.7% for the period. While this was strong, some ASX 200 shares delivered even stronger gains. Here’s...

It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think th...

On Thursday, the S&P/ASX 200 Index (ASX: XJO) ran out of steam and edged into the red. The benchmark index fell slightly to 7,194.9 points. Will the market be able to bounce back from this on Friday? Here are five things to watch: AS...

Telix (ASX:TLX) has released further details of the positive results from its completed pivotal Phase 3 ZIRCON study of TLX250-CDx in clear cell renal cell carcinoma.

MELBOURNE, Australia, June 27, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr...

Wilsons equity strategist Rob Crookston is a happy man. Despite the turbulence in the general market, many of his team’s S&P/ASX 200 Index (ASX: XJO) holdings in the focus portfolio enjoyed earnings upgrades in recent times. Like a pro...

Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme...

The Imugene Limited (ASX: IMU) share price has continued downward in the last 12 months, with the clinical-stage immuno-oncology company declining further in 2023. Unlike the reasonable 3.5% return of the S&P/ASX All Ordinaries Index...

MELBOURNE, Australia, June 22, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-target...

After the S&P/ASX 200 Index (ASX: XJO) broke its near-two week winning streak yesterday, the index today sadly doubled down on those losses. The ASX 200 finished deep in red territory this Thursday. By the end of trading, the index...

MELBOURNE, Australia, June 21, 2023 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business....

The S&P/ASX 200 Index (ASX: XJO) has sadly broken its near-two-week winning streak this Wednesday. After recording a gain every single session since Thursday 8 June, the ASX 200 finished up in the red today. The index closed up shop...

The ASX 200 index slumped by almost half a percent Energy stocks retreated, while Telstra, QBE, Woolworths, and IAG touched new highs Bitcoin has also hit a six-week high   The ASX slipped half a percentage point on Wednesday as traders d...

MELBOURNE, Australia and INDIANAPOLIS, June 21, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Telix (ASX:TLX) has announced that the first patient has been dosed in a global Phase 2 study of its imaging agent TLX250-CDx (89Zr-DFO-girentuximab).

The ASX was trading positively at midday, up almost 0.7 per cent. Most sectors secured gains, with healthcare leading the pack, up nearly two per cent at midday. In ASX news, Iceni Gold (ICL) has made further gold finds along the 15-...

Telix Pharmaceuticals (TLX) doses the first patient for its phase II Starburst study for treating a broad range of cancers The study will look to test the effects of its carbonic anhydrase (CAIX) targeting PET/CT imaging agent TLX250-CD...

MELBOURNE, Australia, June 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeti...

The S&P/ASX 200 Index (ASX: XJO) has ended the trading week on a very high high this Friday. Not only did today’s session mark the ASX’s fifth straight day of gains in a row, but it also left the index at a three-week high. The ASX...

June 21, 2023, at The Yale Club, New York City  Featured speakers and Key Opinion Leaders include: Dr Christian Behrenbruch, Dr Colin Hayward, Kevin Richardson, Dr Brian Shuch and Dr Scott Tagawa Topics include Telix’s urologic pipeline,...

The S&P/ASX 200 Index (ASX: XJO) has closed after another positive session this Wednesday. Following the ASX 200‘s late return to trading this week (thanks to the King’s Birthday holiday), the index ended up adding a healthy 0.32% to...

After a shaky start in the red this morning, the S&P/ASX 200 Index (ASX: XJO) ended up closing higher on Tuesday afternoon. The ASX 200 finished the day at 7,138.9 points, a gain of 0.23% These gains might have been helped by last week...

Telix (ASX:TLX) has officially opened its radiopharmaceutical production facility in Brussels South (Seneffe), in the Wallonia region of Belgium.